Search Results - "Andel, Johannes"

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry by Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Tinchon, Christoph, Petzer, Andreas, Balic, Marija, Heibl, Sonja, Schmitt, Clemens, Zabernigg, August Felix, Egle, Daniel, Sandholzer, Margit, Singer, Christian Fridolin, Roitner, Florian, Hager, Christopher, Andel, Johannes, Hubalek, Michael, Knauer, Michael, Greil, Richard

“…About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene…”
Get full text

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia by Steurer, Michael, Montillo, Marco, Scarfò, Lydia, Mauro, Francesca R, Andel, Johannes, Wildner, Sophie, Trentin, Livio, Janssens, Ann, Burgstaller, Sonja, Frömming, Anna, Dümmler, Thomas, Riecke, Kai, Baumann, Matthias, Beyer, Diana, Vauléon, Stéphanie, Ghia, Paolo, Foà, Robin, Caligaris-Cappio, Federico, Gobbi, Marco

“…Olaptesed pegol (NOX-A12) is a pegylated structured L-oligoribonucleotide that binds and neutralizes CXCL12, a chemokine tightly regulating the life cycle of…”
Get full text

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group by Pleyer, Lisa, Döhner, Hartmut, Dombret, Hervé, Seymour, John F, Schuh, Andre C, Beach, C L, Swern, Arlene S, Burgstaller, Sonja, Stauder, Reinhard, Girschikofsky, Michael, Sill, Heinz, Schlick, Konstantin, Thaler, Josef, Halter, Britta, Machherndl Spandl, Sigrid, Zebisch, Armin, Pichler, Angelika, Pfeilstöcker, Michael, Autzinger, Eva M, Lang, Alois, Geissler, Klaus, Voskova, Daniela, Sperr, Wolfgang R, Hojas, Sabine, Rogulj, Inga M, Andel, Johannes, Greil, Richard

“…We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow…”
Get full text

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study by Piringer, Gudrun, Gruenberger, Thomas, Thaler, Josef, Kührer, Irene, Kaczirek, Klaus, Längle, Friedrich, Viragos-Toth, Istvan, Amann, Arno, Eisterer, Wolfgang, Függer, Reinhold, Andel, Johannes, Pichler, Angelika, Stift, Judith, Sölkner, Lidija, Gnant, Michael, Öfner, Dietmar

“…Background Twenty percent of colorectal cancer liver metastases (CLMs) are initially resectable with a 5-year survival rate of 25%–40%. Perioperative folinic…”
Get full text

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications by Pleyer, Lisa, Burgstaller, Sonja, Stauder, Reinhard, Girschikofsky, Michael, Sill, Heinz, Schlick, Konstantin, Thaler, Josef, Halter, Britta, Machherndl-Spandl, Sigrid, Zebisch, Armin, Pichler, Angelika, Pfeilstöcker, Michael, Autzinger, Eva-Maria, Lang, Alois, Geissler, Klaus, Voskova, Daniela, Geissler, Dietmar, Sperr, Wolfgang R, Hojas, Sabine, Rogulj, Inga M, Andel, Johannes, Greil, Richard

“…The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30,…”
Get full text

QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross‐sectional analysis of the randomized AGMT 02 study by Ludwig, Heinz, Melchardt, Thomas, Schweitzer, Ilvy, Sormann, Siegfried, Schreder, Martin, Andel, Johannes, Hartmann, Bernd, Zojer, Niklas, Schöffmann, Laurenz, Gunsilius, Eberhard, Podar, Klaus, Egle, Alexander, Willenbacher, Wolfgang, Wöll, Ewald, Ruckser, Reinhard, Bozic, Boris, Krauth, Maria‐Theresa, Petzer, Andreas, Schmitt, Clemens, Machherndl‐Spandl, Sigrid, Agis, Hermine, Fillitz, Michael, Wang, Song‐Yau, Knop, Stefan, Greil, Richard

“…Understanding the impact of induction and maintenance therapy on patients’ quality of life (QoL) is important for treatment selection. This study aims to…”
Get full text

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6) by Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Petzer, Andreas, Hubalek, Michael, Petru, Edgar, Sandholzer, Margit, Andel, Johannes, Balic, Marija, Melchardt, Thomas, Hauser-Kronberger, Cornelia, Schmitt, Clemens A., Ulmer, Hanno, Greil, Richard

“…Background: Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast…”
Get full text

P943: OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM‐02) by Ludwig, Heinz, Melchardt, Thomas, Sormann, Siegfried, Schreder, Martin, Andel, Johannes, Hartmann, Bernd, Tinchon, Christoph, Zojer, Niklas, Gunsilius, Eberhard, Podar, Klaus, Egle, Alexander, Willenbacher, Wolfgang, Woell, Ewald, Ruckser, Reinhard, Bozic, Boris, Theresa Krauth, Maria, Petzer, Andreas, Schmitt, Clemens A., Machherndl‐Spandl, Sigrid, Agis, Hermine, Fillitz, Michael, Wang, Song‐Yau, Knop, Stefan, Paiva, Bruno, Greil, Richard

Get full text

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial by Greil, Richard, Prof, Obrtlíková, Petra, MD, Smolej, Lukáš, MD, Kozák, Tomáš, Prof, Steurer, Michael, Prof, Andel, Johannes, MD, Burgstaller, Sonja, MD, Mikušková, Eva, MD, Gercheva, Liana, Prof, Nösslinger, Thomas, MD, Papajík, Tomáš, Prof, Ladická, Miriam, MD, Girschikofsky, Michael, MD, Hrubiško, Mikuláš, Prof, Jäger, Ulrich, Prof, Fridrik, Michael, MD, Pecherstorfer, Martin, Prof, Králiková, Eva, MD, Burcoveanu, Cristina, MD, Spasov, Emil, MD, Petzer, Andreas, Prof, Mihaylov, Georgi, MD, Raynov, Julian, MD, Oexle, Horst, MD, Zabernigg, August, MD, Flochová, Emília, MD, Palášthy, Stanislav, MD, Stehlíková, Olga, Doubek, Michael, Prof, Altenhofer, Petra, MD, Pleyer, Lisa, MD, Melchardt, Thomas, MD, Klingler, Anton, PhD, Mayer, Jiří, Prof, Egle, Alexander, MD

“…Summary Background In many patients with chronic lymphocytic leukaemia requiring treatment, induction therapy with rituximab plus chemotherapy improves…”
Get full text

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial by Schmoll, Hans-Joachim, Wittig, Burghardt, Arnold, Dirk, Riera-Knorrenschild, Jorge, Nitsche, Dieter, Kroening, Hendrik, Mayer, Frank, Andel, Johannes, Ziebermayr, Reinhard, Scheithauer, Werner

“…Purpose This phase II study evaluated the synthetic DNA-based immunomodulator and Toll-like receptor 9 agonist MGN1703 as maintenance treatment in metastatic…”
Get full text

Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14) by Fridrik, Michael A, Jaeger, Ulrich, Petzer, Andreas, Willenbacher, Wolfgang, Keil, Felix, Lang, Alois, Andel, Johannes, Burgstaller, Sonja, Krieger, Otto, Oberaigner, Willi, Sihorsch, Kurt, Greil, Richard

“…Chemoimmunotherapy containing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is the standard treatment for diffuse large…”
Get full text

Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study by Prager, Gerald W., Oehler, Leopold, Gerger, Armin, Mlineritsch, Brigitte, Andel, Johannes, Petzer, Andreas, Wilthoner, Klaus, Sliwa, Thamer, Pichler, Petra, Winder, Thomas, Heibl, Sonja, Gruenberger, Birgit, Laengle, Friedrich, Hubmann, Eva, Korger, Markus, Pecherstorfer, Martin, Djanani, Angela, Neumann, Hans-Joerg, Philipp-Abbrederis, Kathrin, Wöll, Ewald, Trondl, Robert, Arnold-Schrauf, Catharina, Eisterer, Wolfgang

“…Pancreatic cancer (PC) ranks among the deadliest malignancies worldwide. In the MPACT study, first-line nab-paclitaxel plus gemcitabine (nab-P/G) demonstrated…”
Get full text

Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry by Rinnerthaler, Gabriel, Gampenrieder, Simon P, Tinchon, Christoph, Petzer, Andreas Petzer, Balic, Marija, Sonja, Heibl, Zabernigg, August F, Egle, Daniel, Sandholzer, Margit, Roitner, Florian, Andel, Johannes, Pichler, Petra, Hager, Christophe, Hubalek, Michael, Knauer, Michael, Singer, Christian F, Greil, Richard

“…Abstract Background: Despite the advances by targeted therapies, particularly in HER2-positive and hormone receptor (HR)-positive metastatic breast cancer…”
Get full text

Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry by Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Tinchon, Christoph, Petzer, Andreas, Balic, Marij, Heibl, Sonja, Zabernigg, August F, Egle, Daniel, Sandholzer, Margit, Roitner, Florian, Andel, Johannes, Pichler, Petra, Hager, Christopher, Knauer, Michael, Hubalek, Michael, Singer, Christian F, Greil, Richard

“…Abstract Background: BM are generally associated with poor prognosis and with neurological impairments making BM a major limitation of life expectancy and…”
Get full text

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) by Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert

“…Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in…”
Get full text

Hepatic brucellosis detected by 18 F-FDG PET/CT by Nariman, Mehraban Jaromi, Andel, Johannes, Salaheddin, Jarub, Bachmayr, Mario, Pichler, Robert

“…A 52-year old woman with fever of unknown origin underwent fluorine-18-fluorodeoxyglucose ( F-FDG) positron emission tomography/computed tomography (PET/CT)…”
Get full text

Hepatic brucellosis detected by 18F-FDG PET/CT by Nariman, Mehraban Jaromi, Andel, Johannes, Salaheddin, Jarub, Bachmayr, Mario, Pichler, Robert

Get full text

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial) by Ludwig, Heinz, Melchardt, Thomas, Sormann, Siegfried, Zojer, Niklas, Andel, Johannes, Hartmann, Bernd L., Tinchon, Christoph, Gunsilius, Eberhard, Podar, Klaus, Egle, Alexander, Willenbacher, Wolfgang, Wöll, Ewald, Schreder, Martin, Ruckser, Reinhard, Bozic, Boris, Krauth, Maria-Theresa, Petzer, Andreas, Schmitt, Clemens A., Machherndl-Spandl, Sigrid, Agis, Hermine, Fillitz, Michael, Wang, Song-Yau, Knop, Stefan, Kainz, Sarah, Paiva, Bruno, Greil, Richard

Get full text

Abstract PS1-41: Does complete surgical removal of metastases in oligometastatic breast cancer improve survival? A matched-pair analysis of the AGMT_MBC-registry by Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Tinchon, Christoph, Petzer, Andreas Leo, Suppan, Christoph, Heibl, Sonja, Voskova, Daniela, Zabernigg, August F, Egle, Daniel, Sandholzer, Margit, Singer, Christian F, Roitner, Florian, Andel, Johannes, Hubalek, Michael, Knauer, Michael, Greil, Richard

“…Abstract Background: Metastatic breast cancer (MBC) is generally thought to be a systemic and incurable disease requiring systemic therapy. However, surgical…”
Get full text

Abstract PS12-21: First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry by Rinnerthaler, Gabriel, Gampenrieder, Simon P, Tinchon, Christoph, Petzer, Andreas Leo, Suppan, Christoph, Heibl, Sonja, Voskova, Daniela, Zabernigg, August F, Egle, Daniel, Sandholzer, Margit, Singer, Christian F, Roitner, Florian, Andel, Johannes, Hubalek, Michael, Knauer, Michael, Greil, Richard

“…Abstract Background: International guidelines recommend endocrine-based first-line therapy [ET] in hormone receptor-positive, HER2-negative (HR+/HER2- or…”
Get full text